GMR Solutions Q1 2026 earnings and 2026 guidance
GMR Solutions Inc. reported stronger first-quarter 2026 results and issued full-year 2026 guidance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
GMR Solutions Inc. reported stronger first-quarter 2026 results and issued full-year 2026 guidance. Net revenue was $1,457,576, up from $1,367,407, a 6.6% increase, while net income rose to $106,336 from $38,024, a 179.7% gain.
Adjusted EBITDA increased to $305,052 from $278,061, up 9.7%. Net transport revenue per ambulance transport improved to $1,360 from $1,260, and same market revenue grew 7.9%. For full-year 2026, the company guided to net revenue of $5,890 to $6,180 (in millions) and Adjusted EBITDA of $1,135 to $1,195 (in millions).
Positive
- Substantial earnings improvement: Q1 2026 net income rose to 106,336 from 38,024, a 179.7% increase, while Adjusted EBITDA grew 9.7% to 305,052, indicating stronger profitability.
- Supportive 2026 outlook: Full-year 2026 guidance of 5,890–6,180 in net revenue (in millions) and 1,135–1,195 in Adjusted EBITDA (in millions) signals confidence in continued growth.
Negative
- None.
Insights
GMR posts strong Q1 earnings growth and issues solid 2026 guidance.
GMR Solutions Inc. delivered notable operating momentum in Q1 2026. Net revenue grew 6.6% to $1,457,576, while net income jumped to $106,336 from $38,024, a 179.7% increase, reflecting improved profitability versus the prior-year period.
Operationally, Adjusted EBITDA rose 9.7% to $305,052, outpacing revenue growth, suggesting better margin performance. Net transport revenue per ambulance transport increased to $1,360 from $1,260, and same market revenue grew 7.9%, indicating healthier unit economics despite essentially flat total ambulance transports.
Management’s full-year 2026 guidance calls for net revenue between $5,890 and $6,180 (in millions) and Adjusted EBITDA between $1,135 and $1,195 (in millions). The company also expects cash used for net capital expenditures and aircraft financing to be 5.1–5.3% of net revenue, framing anticipated investment needs alongside profitability targets.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
Net transport revenue per ambulance transport financial
Redeemable preferred stock financial
Payor mix financial
Emergent transports financial
Earnings Snapshot
For full-year 2026, GMR projects net revenue of 5,890–6,180 (in millions) and Adjusted EBITDA of 1,135–1,195 (in millions), with cash used for net capital expenditures and aircraft financing at 5.1–5.3% of net revenue.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did GMR Solutions Inc. (GMRS) perform financially in Q1 2026?
What full-year 2026 guidance did GMR Solutions Inc. (GMRS) provide?
How did GMR Solutions Inc.’s profitability metrics change year over year?
What operational metrics did GMR Solutions Inc. (GMRS) highlight for Q1 2026?
What does the payor mix look like for GMR Solutions Inc. in Q1 2026?
How did GMR Solutions Inc.’s cash flow from operations change in Q1 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant To Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | | (Commission File Number) | | (I.R.S. Employer |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: | | Trading Symbol | | Name of each exchange on which registered: |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On June 1, 2026, GMR Solutions Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. | | Description of Exhibit |
99.1 | Press release of GMR Solutions Inc. dated June 1, 2026 | |
104 | Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 1, 2026 | ||
By: | /s/ Brian Tierney | |
Name: | Brian Tierney | |
Title: | Executive Vice President and Chief Financial Officer | |
3
Exhibit 99.1
GMR Solutions Inc. Reports First Quarter 2026 Financial Results
and Establishes Full Year 2026 Guidance
LEWISVILLE, Texas (June 1, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of emergency medical services (“EMS”), today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance.
First Quarter 2026 Financial Highlights
| ● | Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 |
| ● | Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 |
| ● | Adjusted EBITDA(1) of $305.1 million, up 9.7% compared to $278.1 million in the first quarter of 2025 |
| ● | Maintained strong liquidity position, in excess of $1.1 billion, comprised of $426.1 million of cash and cash equivalents and approximately $691.6 million of available borrowing capacity on the ABL Facility as of March 31, 2026 |
| ● | Redeemed 189,050 shares of Preferred Stock for an aggregate redemption price of approximately $250.0 million on March 6, 2026 |
“GMR’s first-quarter performance reflects the strength of our strategy and the discipline with which we are executing it,” said Nick Loporcaro, Chairman and Chief Executive Officer of GMR. “Our teams continue to deliver solid top-line and net income growth, while staying focused on our core mission-critical services. Taken together, these results reinforce our confidence that GMR has the right foundation, the right financial discipline, and the right growth opportunities to create long-term value and expand our services.”
Key Financials
| | Three Months Ended | | |
| ||||
| | March 31 | | |
| ||||
| | 2026 | | 2025 | | % | | ||
($in millions) | | (Unaudited) | | |
| ||||
Net revenue | | $ | 1,457,576 | | $ | 1,367,407 |
| 6.6% | |
| | Three Months Ended | | |
| ||||
| | March 31 | | |
| ||||
| | 2026 | | 2025 | | % | | ||
($in millions) | | (Unaudited) | | |
| ||||
Net income | | $ | 106,336 | | $ | 38,024 |
| 179.7% | |
| | Three Months Ended | | |
| ||||
| | March 31, | | |
| ||||
| | 2026 | | 2025 | | % | | ||
($in millions) | | (Unaudited) | | |
| ||||
Adjusted EBITDA(1) | | $ | 305,052 | | $ | 278,061 |
| 9.7% | |
1 | Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the end of this press release for a reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). |
1
Business Metrics
| | Three Months Ended |
| ||||
| | March 31, | | ||||
| | 2026 | | 2025 |
| ||
(in thousands) | | (Unaudited) |
| ||||
Patient encounters | | |
| ||||
Emergent transports |
| | 837,443 |
| | 831,913 | |
Non emergent transports |
| | 204,709 |
| | 220,584 | |
Total ambulance transports |
| | 1,042,152 |
| | 1,052,497 | |
of which, Ground transports |
| | 1,007,810 |
| | 1,018,536 | |
of which, Flights |
| | 34,342 |
| | 33,961 | |
Wheelchair transports |
| | 7,828 |
| | 16,577 | |
Non-transport |
| | 273,920 |
| | 276,036 | |
Total patient encounters |
| | 1,352,022 |
| | 1,364,281 | |
of which, Nurse Navigation encounters |
| | 28,122 |
| | 19,171 | |
| | | | | | | |
Net transport revenue per ambulance transport | | $ | 1,360 | | $ | 1,260 | |
| | | | | | | |
Other key performance indicators: | |
| | |
| | |
Emergent air transport requests | |
| 75,213 | |
| 75,841 | |
Weather cancellation rate for emergent air transports | |
| 17.1 | % |
| 17.9 | % |
Same market revenue growth | |
| 7.9 | % |
| 14.9 | % |
Net cash capital expenditures | | $ | 54,011 | | $ | 38,629 | |
Cash used in aircraft financing arrangements | | $ | 24,992 | | $ | 25,095 | |
| | | | | | | |
Payor mix (as a percentage of net transport revenue): | |
| | |
| | |
Medicare | |
| 25 | % |
| 26 | % |
Medicaid | |
| 9 | % |
| 9 | % |
Commercial insurance and managed care | |
| 57 | % |
| 56 | % |
Other third-party payors | |
| 7 | % |
| 7 | % |
Self-pay | |
| 2 | % |
| 2 | % |
Net transport revenue | |
| 100 | % |
| 100 | % |
Full Year 2026 Financial Guidance
GMR is establishing the following guidance for the full year 2026:
(in millions) | | Range for the year ending | ||||
| | December 31, 2026 | ||||
| | Low | | High | ||
Net revenue | | $ | 5,890 | | $ | 6,180 |
| |
| | |
| |
Adjusted EBITDA(2) | | $ | 1,135 | | $ | 1,195 |
| | | | | | |
Cash used for net capital expenditures and aircraft financing as a percent of net revenue | | | 5.1% | | | 5.3% |
2 | A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results. |
2
Webcast and Conference Call Details
The Company will host a conference call tomorrow, June 2, 2026, at 10 a.m. Eastern Time. Investors can access the live call by joining the following link https://events.q4inc.com/attendee/146682024.
An archived webcast of the event will be available on the “Events & Presentations” section of the GMR website at https://investors.globalmedicalresponse.com/. The Company has posted supplemental information on the first quarter 2026 results that it will reference during the conference call. The supplemental information can be found under the “Financials” tab on the Company’s investor relations page. Following the live event, replays will be available via webcast for one year at https://investors.globalmedicalresponse.com/.
About Global Medical Response
GMR is the nation’s largest provider of EMS, delivering EMS and other essential out-of-hospital care in rural and urban communities that represent more than 60% of the U.S. population. As the only national, fully integrated, air and ground EMS provider, GMR operates in approximately 1,400 counties across the country. A recognized innovator, GMR develops new solutions to meet evolving industry needs and expand access to high-quality care. With roughly 34,000 team members, GMR supports roughly 5.5 million patient encounters annually and performs a critical care intervention every 88 seconds. Its family of solutions includes ambulance EMS provider American Medical Response, as well as multiple air EMS organizations including Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International.
We may use our website (www.globalmedicalresponse.com), Facebook page (www.facebook.com/GlobalMedicalResponse), X (Twitter) (www.x.com/GMR_Social), LinkedIn (www.linkedin.com/company/Global-Medical-Response), and Instagram (www.instagram.com/Global_Medical_Response), accounts as channels of distribution of company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission (“SEC”) filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Investor Email Alerts” section of our website at https://investors.globalmedicalresponse.com/resources/investor-email-alerts/default.aspx. The contents of our website, any alerts and social media channels are not, however, a part of this press release.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts , including statements related to our ability to create long-term value and expand our services and statements regarding our financial guidance. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, you can identify these forward-looking statements by the use of words such as “anticipate,” “assume,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “future,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negative version of these words, or similar terms and phrases.
The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:
| ● | if we receive fewer emergency transport requests or fewer non-emergency ambulance transport requests, our revenue could be adversely effected; |
| ● | shifts in payor mix could decrease our revenue; |
| ● | changes in the rates paid by, or the coverage or reimbursement methodology used by, commercial insurers, and delays in collection or non-collection of our accounts receivable could adversely affect us; |
| ● | reduction in governmental rates for our services, limitations in funding for our services, or reduction in the number of individuals eligible for Medicare and Medicaid programs could adversely impact our business; |
| ● | our business could be materially adversely affected if we are not able to maintain or reduce costs to provide our services; |
| ● | we have a history of losses and can provide no assurance of our future operating results; |
| ● | federal and state “surprise medical billing” legislation and regulations could adversely affect us; |
3
| ● | deterioration in the collectability of patient responsibility accounts or charges for uninsured patients could reduce our revenue; |
| ● | adverse weather conditions and physical impacts of climate change affect our helicopter emergency air ambulance operations, which could adversely impact our results of operations; |
| ● | the inability to maintain our corporate reputation and relationships with existing patient referral sources or establish new referral sources could materially adversely affect us; |
| ● | loss of existing contracts, including ground ambulance contracts and our EMS partnership with the Federal Emergency Management Agency, could adversely affect our revenue; |
| ● | our inability to attract and retain qualified and skilled personnel could adversely affect us; |
| ● | our business requires substantial capital expenditures and working capital financing, which we may be unable to obtain on satisfactory terms or at all; |
| ● | our dependency on a limited number of third-party vendors for certain equipment and services could impair our ability to obtain the equipment and services we need to operate our business; |
| ● | inflationary pressure, particularly increases in fuel costs, could negatively impact our operations; |
| ● | our emphasis on servicing rural communities exposes us to risks; |
| ● | accidents or other incidents involving patient transport operations could materially and adversely affect our reputation, business, financial condition, results of operations and cash flows; |
| ● | any failure by us to manage or integrate acquisitions, divestitures, and other significant transactions successfully may have a material adverse effect on us; |
| ● | if we fail to manage organizational change effectively, we may be unable to execute our business plan, maintain our high levels of service or adequately address competitive challenges; |
| ● | our business may be materially and adversely affected if we are unable to ensure that our services interoperate with operating systems, devices and software and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; |
| ● | impairment of our goodwill or other intangible assets may adversely impact us; |
| ● | cybersecurity incidents could disrupt business operations, result in the unauthorized access to or disclosure or use of critical and other sensitive or regulated data or confidential information and adversely impact us; |
| ● | our use or our third-party service providers’ or business partners’ use of Machine Learning Technologies and the evolving regulatory framework in this area could materially or adversely affect us; |
| ● | we are subject to risks related to payment processing; |
| ● | hospital capacity and the ability of hospitals to treat the patients we transport can impact our business; |
| ● | our business may be harmed by labor relation matters; |
| ● | we may be adversely affected if we are unable to retain any member of our senior management; |
| ● | adverse changes in general economic conditions and reductions in consumer spending could adversely impact the patients and the hospitals that use our services; |
| ● | competition from other air or ground ambulance providers may adversely affect our business; |
| ● | we may be subject to substantial malpractice or other similar claims and insurance coverage for some of our losses may be inadequate and may be subject to the credit risk of commercial insurance companies; |
| ● | the reserves established for our losses covered under insurance programs are subject to inherent uncertainties; |
| ● | risks relating to payments to tax receivable agreement parties for certain tax benefits; |
| ● | risks relating to our compliance with our legal and regulatory framework; |
| ● | continued regulatory and public scrutiny of private equity’s role in EMS and healthcare may limit our ability to acquire operations, expand in certain states, or otherwise materially and adversely affect our reputation, business, operations and financial condition; |
| ● | our inability or failure to obtain, maintain, protect or enforce our intellectual property rights could adversely affect our business; |
| ● | our substantial indebtedness could adversely affect our financial condition; |
| ● | we will be a “controlled company” within the meaning of the rules of the New York Stock Exchange and the rules of the SEC and, as a result, qualify for, and intend to rely on, exemptions from certain corporate governance requirements; |
| ● | KKR, and funds affiliated with it, controls us and its interests may conflict with yours in the future; and |
| ● | regulations limit foreign ownership of us, which could reduce the price of our Class A common stock and cause owners of our Class A common stock who are not U.S. persons to lose their voting rights. |
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and in our filings with the SEC, including the information under the captions “Risk Factors” in GMR’s final prospectus (the “IPO Prospectus”) in connection with our initial public offering (the “IPO”), filed with the SEC and dated May 12,
4
2026, as well as GMR’s subsequent other filings with the SEC from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.
Any forward-looking statement made by us herein speaks only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included herein. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. For additional information on these and other factors that could cause GMR’s actual results to differ materially from expected results, please see our filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and on the “Investor Relations” tab of our website.
Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, we make use of the non-GAAP financial measures “EBITDA” and “Adjusted EBITDA.”
We provide non-GAAP financial information to enhance the understanding of our GAAP financial information and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies.
We define EBITDA as net income (loss) before interest expense, net, income tax provision (benefit), and depreciation and amortization. We define Adjusted EBITDA as EBITDA, as further adjusted to exclude management fees, non-cash stock-based compensation, professional fees and other expenses for non-recurring matters, debt financing fees paid to (received from) third parties and certain other items that we do not consider indicative of our ongoing operating performance.
Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, to report compliance with certain covenants in our debt agreements and to compare our performance against that of peer companies using similar measures. Moreover, we present EBITDA and Adjusted EBITDA because we believe that investors consider them to be important supplemental measures of our performance and believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry.
Adjusted EBITDA is an analytical indicator used by management and the healthcare industry to evaluate company performance, allocate resources and measure leverage. Adjusted EBITDA should not be considered in isolation or as an alternative to net income (loss), cash flows from operations, investing or financing activities, or other financial statement data presented in the unaudited condensed consolidated financial statements as indicators of financial performance. Because Adjusted EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies and may not be comparable to similarly titled measures used in debt compliance calculations. Net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most comparable to Adjusted EBITDA, as defined.
GMR Contacts:
Media Contact:
Kirsten Gurmendi
Public Relations Director, GMR Solutions Inc.
media@gmr.net
877.418.2980
Investor Contact:
Krister Sorensen
Vice President, Investor Relations, GMR Solutions Inc.
Investor.relations@gmr.net
5
GMR Solutions Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
March 31, 2026 and December 31, 2025
(Amounts in thousands)
| | March 31, | | December 31, | ||
| | 2026 | | 2025 | ||
ASSETS | | (unaudited) | | | | |
Current assets: |
| | |
| | |
Cash and cash equivalents | | $ | 426,092 | | $ | 609,349 |
Insurance collateral | |
| 74,396 | |
| 78,608 |
Accounts receivable, net | |
| 1,159,661 | |
| 1,094,814 |
Spare parts, medical supplies and fuel | |
| 123,772 | |
| 115,725 |
Prepaid expenses | |
| 75,808 | |
| 105,014 |
Other current assets | |
| 135,098 | |
| 128,571 |
Total current assets | |
| 1,994,827 | |
| 2,132,081 |
Property and equipment, net of accumulated depreciation of $1,269,762 and $1,223,603 at March 31, 2026 and December 2025, respectively | |
| 1,364,127 | |
| 1,361,278 |
Operating right-of-use assets | |
| 207,786 | |
| 203,258 |
Finance right-of-use assets | |
| 88,730 | |
| 85,030 |
Intangible assets, net | |
| 1,188,075 | |
| 1,204,237 |
Goodwill | |
| 2,180,581 | |
| 2,180,581 |
Other assets | |
| 316,509 | |
| 315,580 |
Total assets | | $ | 7,340,635 | | $ | 7,482,045 |
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY | | | | | | |
Current liabilities: | | | | | | |
Accounts payable | |
| 65,822 | |
| 60,047 |
Accrued wages, benefits and taxes | |
| 264,812 | |
| 339,710 |
Accrued interest | |
| 91,504 | |
| 75,655 |
Other accrued liabilities | |
| 423,468 | |
| 363,160 |
Current portion of lease obligations | |
| 80,562 | |
| 78,717 |
Current portion of long-term debt | |
| 141,809 | |
| 147,140 |
Total current liabilities | |
| 1,067,977 | |
| 1,064,429 |
Operating lease obligations | |
| 174,179 | |
| 171,880 |
Finance lease obligations | |
| 79,314 | |
| 74,943 |
Long-term debt | |
| 4,894,435 | |
| 4,898,769 |
Deferred income taxes | |
| 208,947 | |
| 209,067 |
Insurance reserves | |
| 310,619 | |
| 312,069 |
Other long-term liabilities | |
| 100,026 | |
| 101,593 |
Total liabilities | |
| 6,835,497 | |
| 6,832,750 |
Commitments and contingencies | |
| | |
| |
Mezzanine equity: | | | | | | |
Redeemable preferred stock | |
| 292,469 | |
| 445,140 |
Total mezzanine equity | |
| 292,469 | |
| 445,140 |
Stockholders’ equity: | | | | | | |
Common stock, $0.0001 par value, 200,000,000 shares authorized and 22,096,835 and 22,096,835 shares issued and outstanding, respectively | |
| 2 | |
| 2 |
Additional paid-in capital | |
| 359,052 | |
| 456,466 |
Retained earnings (deficit) | |
| (153,156) | |
| (259,492) |
Accumulated other comprehensive income (loss) | |
| 6,771 | |
| 7,179 |
Total stockholders' equity (deficit) | |
| 212,669 | |
| 204,155 |
Total liabilities, mezzanine equity and stockholders' equity | | $ | 7,340,635 | | $ | 7,482,045 |
6
GMR Solutions Inc. and Subsidiaries
Consolidated Statements of Operations
For the three months ended March 31, 2026 and 2025
(Amounts in thousands, except share and per share amounts, unaudited)
| | Three Months Ended | ||||
| | March 31, | ||||
| | 2026 | | 2025 | ||
Net revenue | | $ | 1,457,576 | | $ | 1,367,407 |
Operating expenses: | | | | | | |
Employee wages, benefits and taxes | | | 770,006 | | | 734,758 |
Maintenance, fuel and other direct expenses | | | 118,620 | | | 111,811 |
Insurance expense | | | 42,979 | | | 33,652 |
Other operating expenses | | | 228,094 | | | 215,806 |
Depreciation and amortization | | | 75,367 | | | 75,127 |
Impairment of assets held for sale and other investments | | | — | | | 14,100 |
Acquisition, integration and other charges | | | 3,612 | | | 4,301 |
Total operating expenses | | | 1,238,678 | | | 1,189,555 |
Operating income | | | 218,898 | | | 177,852 |
Interest expense, net | | | 83,174 | | | 113,685 |
Equity in (earnings) losses of unconsolidated affiliates | | | (463) | | | (2,302) |
Other (income) loss, net | | | (6,344) | | | (922) |
Net income (loss) before income taxes | | | 142,531 | | | 67,391 |
Income tax (benefit) expense | | | 36,195 | | | 29,367 |
Net income (loss) | | $ | 106,336 | | $ | 38,024 |
| | | | | | |
Net income (loss) available to common stockholders per share: | |
| | |
| |
Basic | | $ | 0.92 | | $ | (0.03) |
Diluted | | $ | 0.28 | | $ | (0.03) |
Weighted-average common shares outstanding: | |
| | |
| |
Basic | |
| 45,836,749 | |
| 45,551,279 |
Diluted | |
| 149,275,141 | |
| 45,551,279 |
| | | | | | |
Comprehensive income (loss): | |
| | |
| |
Net income (loss) | |
| 106,336 | |
| 38,024 |
Other comprehensive income (loss) | |
| | |
| |
Unrealized holding gains (losses) on investments | |
| (524) | |
| 468 |
Deferred income tax benefit (expense), net | |
| 116 | |
| (104) |
Total other comprehensive income (loss), net of income tax | |
| (408) | |
| 364 |
Comprehensive income (loss) | | $ | 105,928 | | $ | 38,388 |
7
GMR Solutions Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the three months ended March 31, 2026 and 2025
(Amounts in thousands, unaudited)
| | Three Months Ended | ||||
| | March 31, | ||||
| | 2026 | | 2025 | ||
Cash flows from operating activities: | | | | | | |
Net income (loss) | | $ | 106,336 | | $ | 38,024 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | | | | | | |
Depreciation and amortization | |
| 75,367 | |
| 75,127 |
Amortization of deferred financing costs and debt discount | |
| 2,389 | |
| 4,094 |
Paid-in-kind interest on long-term debt | |
| — | |
| 7,757 |
Impairment of assets held for sale and other investments | |
| — | |
| 14,100 |
(Gain) loss on divestiture of businesses | |
| — | |
| (1,422) |
Stock-based compensation expense | |
| (91) | |
| 520 |
Liability classified stock awards | |
| — | |
| 2,085 |
Loss (gain) on disposal of property and equipment | |
| 1,076 | |
| 4,105 |
Unrealized loss (gain) on marketable equity securities | |
| 1,227 | |
| 1,235 |
Deferred income taxes | |
| (4) | |
| (1) |
Other, net | |
| (7,364) | |
| (2,302) |
Changes in assets and liabilities, net of effects of acquisitions | | | | | | |
Accounts receivable, net | |
| (64,847) | |
| (61,631) |
Accounts payable | |
| 5,775 | |
| 3,050 |
Accrued wages, benefits and taxes | |
| (73,169) | |
| (34,704) |
Accrued interest | |
| 15,849 | |
| 65,712 |
Accrued liabilities | |
| 54,375 | |
| 47,643 |
Other assets and liabilities, net | |
| 11,824 | |
| 25,951 |
Net cash provided by (used in) operating activities | |
| 128,743 | |
| 189,343 |
Cash flows from investing activities: | | | | | | |
Proceeds from divestiture of businesses | |
| — | |
| 6,422 |
Proceeds from asset disposals related to sales and insurance recoveries | |
| 1,199 | |
| 265 |
Purchases of property and equipment | |
| (64,138) | |
| (52,458) |
Net change in investments held as insurance collateral | |
| (660) | |
| (734) |
Purchases of marketable securities | |
| (25,878) | |
| (10,150) |
Sales and maturities of marketable securities | |
| 24,819 | |
| 12,852 |
Other investing activities, net | |
| 13,200 | |
| (4,613) |
Net cash provided by (used in) investing activities | |
| (51,458) | |
| (48,416) |
Cash flows from financing activities: | | | | | | |
Payments on finance lease obligations | |
| (3,016) | |
| (3,493) |
Principal payments on long-term debt | |
| (39,491) | |
| (36,084) |
Proceeds from issuance of long-term debt | |
| 27,681 | |
| 10,000 |
(Redemption) issuance of redeemable preferred stock | |
| (249,994) | |
| — |
Proceeds from issuance of shares under stock award plan, net of cash taxes paid | |
| — | |
| 498 |
Net cash provided by (used in) financing activities | |
| (264,820) | |
| (29,079) |
(Decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | |
| (187,535) | |
| 111,848 |
Cash and cash equivalents, beginning of period (including restricted cash and restricted cash equivalents of $14.8 million and $16.6 million, respectively) | |
| 624,229 | |
| 368,902 |
Cash and cash equivalents, end of period (including restricted cash and restricted cash equivalents of $10.6 million and $15.6 million, respectively) | | $ | 436,694 | | $ | 480,750 |
| | | | | | |
Supplemental disclosure of cash flow information | | | | | | |
Equipment (primarily aircraft) additions financed with the issuance of debt | | $ | — | | $ | 4,131 |
Cash paid (received) during the period for: | | | | | | |
Interest | | $ | 76,324 | | $ | 36,126 |
Income taxes, net of refunds received | | $ | (878) | | $ | 1,099 |
8
GMR Solutions Inc. and Subsidiaries
Reconciliation of EBITDA and Adjusted EBITDA
For the three months ended March 31, 2026 and 2025
(Amounts in thousands, unaudited)
The following table reconciles net income to EBITDA and Adjusted EBITDA:
| | Three Months Ended | | |
| ||||
| | March 31, | | 2026 v. | | ||||
| | 2026 | | 2025 | | 2025 Change |
| ||
Net income (loss) | | $ | 106,336 | | $ | 38,024 | | 179.7 | % |
Interest expense, net | |
| 83,174 | |
| 113,685 |
| (26.8) | % |
Income tax provision (benefit) | |
| 36,195 | |
| 29,367 |
| 23.3 | % |
Depreciation and amortization | |
| 75,367 | |
| 75,127 |
| 0.3 | % |
EBITDA | | $ | 301,072 | | $ | 256,203 |
| 17.5 | % |
Management fees(1) | |
| 2,977 | |
| 2,705 |
| 10.1 | % |
Stock-based compensation(2) | |
| (91) | |
| 2,605 |
| (103.5) | % |
Professional fees and other expenses for non-recurring matters(3) | |
| 6,911 | |
| 4,554 |
| 51.8 | % |
Debt refinancing fees paid to (received from) third parties(4) | |
| 320 | |
| 383 |
| (16.4) | % |
Impairment of assets held for sale and other investments(5) | |
| — | |
| 14,100 |
| (100.0) | % |
(Gain) loss on divestiture of businesses(6) | |
| — | |
| (1,422) |
| (100.0) | % |
Realized and unrealized (gain) loss, net(7) | |
| (5,674) | |
| 1,235 |
| (559.4) | % |
Equity method investment (income) loss(8) | |
| (463) | |
| (2,302) |
| (79.9) | % |
Adjusted EBITDA | | $ | 305,052 | | $ | 278,061 |
| 9.7 | % |
| (1) | Represents management/director fees paid to directors and Kohlberg Kravis Roberts & Co. L.P. (the “Manager”) in connection with the ownership and financial management of the Company and procurement diagnostics and operational support provided by the Manager and its affiliates, including under the Monitoring Agreement (as defined in the IPO Prospectus). The Monitoring Agreement was terminated upon completion of the IPO. See “Certain Relationships and Related Party Transactions” in the IPO Prospectus for further information. |
| (2) | Represents the stock compensation expense associated with the vesting of stock options and other equity awards, as well as the estimate of achievement of the cash-settled performance stock units. |
| (3) | Represents fees and expenses incurred in connection with certain business combinations and divestitures, as well as other fees and expenses incurred in connection with distinct transactions and matters unrelated to our normal and continued business operations, as further described below: |
| | Three Months Ended | ||||
| | March 31, | ||||
(in thousands) | | 2026 | | 2025 | ||
| | | | | | |
Acquisition and divestiture fees paid to (received from) third parties(i) | | | 1,406 | | | 2,014 |
Executive management severance fees(ii) |
| | 1,202 |
| | 782 |
Legal settlements and government affairs(iii) |
| | 1,007 |
| | 854 |
Other(iv) |
| | 3,296 |
| | 904 |
Total professional fees and other expenses for non-recurring matters | | $ | 6,911 | | $ | 4,554 |
| (i) | Represents fees incurred in connection with potential and completed business combinations and divestitures of certain asset groups. These costs primarily represent diligence costs, transaction costs, and integration costs, and consist primarily of third party financial advisory, legal, and consulting fees. Such costs are specific to acquisition and divestiture activity that would not have otherwise been incurred in connection with our ordinary course business operations. |
| (ii) | Fees incurred in the three months ended March 31, 2026 and 2025 primarily related to severance costs in connection with our targeted market exit strategies executed during such periods, in each case, to optimize our cost structure and enhance our operating effectiveness. These activities were undertaken to meet specific business objectives. In addition, these amounts represent discrete costs outside the ordinary course of business that are distinct from normal, recurring operating expenses. |
9
| (iii) | For the periods presented, amounts primarily relate to certain regulatory initiatives in California that are non-routine and not expected to continue. |
| (iv) | Represents other third-party fees and expenses incurred in connection with distinct transactions and matters unrelated to our normal and continued business operations, including major system implementation and enhancements relating to the integration of our timekeeping and electronic patient care charting systems. |
| (4) | Represents fees associated with our long-term debt refinancing consummated during fiscal year 2025, which primarily consisted of fees incurred for third party legal, accounting and tax consulting in connection with the debt refinancing. |
| (5) | Impairment of assets held for sale and other investments includes impairment charges of $14.1 million related to a strategic cost investment for the three months ended March 31, 2025. There was no impairment on assets held for sale or strategic cost investments for the three months ended March 31, 2026. |
| (6) | (Gain) loss on divestiture of businesses for the three months ended March 31, 2025 was $1.4 million related to net working capital finalization for the divestiture of our coordinated care business. For the three months ended March 31, 2026, there was no (gain) loss on divestiture of businesses recorded. |
| (7) | Realized and unrealized (gain) loss, net represents changes in the fair value of equity securities. Additionally, during the three months ended March 31, 2026, a certain cost method investment was sold for a (gain) of ($6.9) million. |
| (8) | We use the equity method of accounting to recognize our proportionate share of net income (loss) generated by our noncontrolling interest in Banner health system emergency air joint venture in Arizona. |
10